"Several promising vaccines are in late stage development and are preparing for regulatory review in the United States and internationally," notes Kalorama Information analyst Melissa Elder. "Many of the products -- including OncoVAX, TroVAX, and Lucanix -- are already in Phase III development, have orphan drug status, SPA status, or Fast Track status, which promises a bright future for many of these products."

These vaccines will, however, have to overcome a few hurdles, including the reimbursement issue. Manufacturers must not only demonstrate that new vaccines are superior to other products on the market but also that pharmacogenomics and personalized medicine are worth the anticipated additional cost.

Kalorama Information's report "Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition," focuses on both preventative and therapeutic cancer vaccines in development. A market overview, cancer statistics, market estimates and forecasts for 2008-2012 are included, as well as discussions of current issues and trends affecting the industry.

SOURCE: Kalorama Information